Methylene Blue for Refractory Shock in Children: A Systematic Review and Survey Practice Analysis.

What It Covers

This systematic review looks at Methylene blue (non-peptide stack partner).

The use of methylene blue to treat refractory shock in children is not well described.

The researchers aim to collect and summarize the literature and define physicians' practice patterns regarding the use of methylene blue to treat shock in children.

Who the Included Studies Covered

PubMed indexes the participants as children and adults.

Patients less than or equal to 25 years old with refractory shock treated with methylene blue.

How the Review Was Done

The researchers conducted a systematic search of MEDLINE, Embase, PubMed, Web of Science, Cochrane for studies involving the use of methylene blue for catecholamine-refractory shock from database inception to 2019.

Collected studies were analyzed qualitatively.

To describe practice patterns of methylene blue use, the researchers electronically distributed a survey to U.S.-based pediatric critical care physicians.

The researchers assessed physician knowledge and experience with methylene blue.

Survey responses were quantitatively and qualitatively evaluated.

What Was Measured

Topics PubMed links to this paper include Catecholamines, Methylene Blue, Shock and Surveys and Questionnaires.

What This Means in Plain Language

This is a systematic review of Methylene blue (non-peptide stack partner).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.